'Elite neutralizing' antibody demonstrates long-term viral suppression in persons living with HIV in phase 1 trial
Written by: Jacqueline Mitchell Contact: Chloe Meck, firstname.lastname@example.org
OCTOBER 14, 2021
BOSTON – In the 40 years since the first published reports of the syndrome known as AIDS, more than 32 million people have died from the virus that causes it, the human immunodeficiency virus (HIV). With more than 35 million people worldwide living with HIV today and nearly two million new cases each year, HIV remains a major global epidemic.
Broadly neutralizing monoclonal antibodies (bNAB) target specific proteins on the outside of the virus. In a phase 1 clinical trial, researchers led by physicians-scientists at Beth Israel Deaconess Medical Center (BIDMC) evaluated an antibody known as PGT121 for its ability to treat and prevent HIV-1 infection. The scientists found that the antibody was safe and well-tolerated by trial participants and also demonstrated antiviral activity in adults living with HIV. The team’s results appear in Nature Medicine.
After establishing the antibody’s safety and tolerability in a placebo-controlled trial including adults living with and without HIV and adults living with HIV taking anti-retroviral therapy (ART) to suppress their viral infection, the scientists next evaluated the antibody in adults living with HIV who were not taking ART who therefore had detectible viral loads. Among the 13 participants enrolled in this part of the trial, nine participants were found to have high viral loads at baseline (more than 2,000 viral copies per milliliter of blood) and four were found to have low baseline viral loads (fewer than 2,000 copies.)
Following a single dose of the antibody, viral load declined among those with high baseline viral counts and continued to decrease for seven to 10 days before rebounding to baseline by day 28. In the low viral load group, all four participants saw a decrease in viral load, with two participants’ numbers rebounding to baseline by day 28. However, two participants exhibited much longer viral suppression.
“Notably, two individuals with a low viral load at baseline demonstrated drug-free viral suppression for more than 168 days – nearly six months – following a single infusion of the antibody,” said corresponding author Dan H. Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at BIDMC. “Viral rebound was not detected in one participant until the individual was brought back for a long-term extension of the study at day 252. To our knowledge, this is the longest observed ART-free viral load suppression reported in the literature following one dose of any single or combined broadly neutralizing antibody treatment for HIV.”
Consistent with previous studies of antibody treatments for HIV, the scientists also observed the emergence of at least partial resistance to the antibody in 12 of the 13 participants – HIV’s ability to rapidly evolve resistance to drug therapies and vaccine strategies is one reason the virus has been so difficult to eradicate. However, the current study’s findings suggest the investigative antibody may have greater potency than other single broadly neutralizing antibodies tested thus far, the researchers noted.
“In summary, the antibody treatment was safe, well-tolerated and had a brisk antiviral affect in participants living with HIV-1 who had a detectable viral load,” said co-first author Kathryn E. Stephenson, MD, MPH, an investigator in the Center for Virology and Vaccine Research at BIDMC and protocol co-chair with Boris Julg, MD, PhD of the “T001” Clinical Trial. “These data suggest that this antibody should be tested further for its ability to maintain viral suppression or to block HIV infection, particularly in combination with other broadly neutralizing antibodies.”
Co-authors included Boris Julg, C. Sabrina Tan, Rebecca Zash, Stephen R. Walsh, Jessica Ansel, Diane G. Kanjila, Lori F. Maxfield, Joseph Nkolola, Erica N. Borducchi, Peter Abbink, Jinyan Liu, Lauren Peter, Abishek Chandrashekar, Ramya Mityanandam, Zijin Lin, Alessandra Setaro, Joseph Sapiente and Michael S. Seaman of BIDMC; Zhilin Chen of Ragon Institute of MGH, MIT and Harvard; Charlotte-Paige Rolle and Edwin DeJesus of Orlando Immunology Center; Ana N. Monczor, Sofia Lupo, Roberto C. Arduino of McGovern Medical School at The University of Texas Science Center at Houston; Huub C. Gelderblom, Lisa Sunner, Frances H. Priddy of International AIDS Vaccine Initiative; Tyler Cassidy, Alan S. Perelson, Elena E. Giorgi and Bette Korber of Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; Chelsey Bennet, Alicia Sato and Bryan Mayer of Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center; Nicole L. Yates and Georgia D. Tomaras of Duke University.
This work was supported by the Bill & Melinda Gates Foundation Collaboration for AIDS Vaccine Discovery (grant OPP1107669) and the National Institutes of Health (NIH) (grants AI 149670, AI145801. AI129797, AI128751, AI126603, AI124377, OD024917, AI106408, TR001102 and AI114381). Portions of this work were performed under the auspices of the US Department of Energy and supported by NIH grants AI028433, OD011095 and AI121365.
All authors declare no competing interests.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox.
Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,800 physicians and 36,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.